Loading...
OTCM
PXMTF
Market cap86mUSD
, Last price  
USD
Name

Erytech Pharma SA

Chart & performance

D1W1MN
OTCM:PXMTF chart
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
-22.30%
Rev. gr., 5y
12.50%
Revenues
0
3,461,0001,802,0006,613,00010,776,00019,719,0003,364,0004,138,0003,364,000000
Net income
-228k
L-99.58%
-2,172,000-8,145,000-8,860,000-15,013,000-21,913,000-33,530,000-38,224,000-62,659,000-73,300,000-53,797,000-228,000
CFO
-32m
L-44.05%
621,402-6,473,233-7,238,532-14,578,000-17,614,000-24,702,000-39,270,000-43,310,000-51,720,000-56,770,000-31,764,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

ERYTECH Pharma S.A. is a biopharmaceutical company specializing in the clinical development of red blood cell-based treatments for various cancers and orphan diseases. Its operations are based in France and the United States. The company's most advanced investigational therapy, eryaspase, is currently undergoing Phase 3 clinical trials for second-line pancreatic cancer, and Phase 2 studies for patients with triple-negative breast cancer and second-line acute lymphoblastic leukemia. Furthermore, ERYTECH is developing erymethionase, a preclinical candidate that employs methionine-γ-lyase encapsulated in red blood cells to target methionine-dependent tumors. Founded in 2004, the firm's headquarters are located in Lyon, France.

Key people

Jerome Bailly
Deputy Chief Executive Officer - Chief Pharmacist · since 2011
Eric Soyer
Chief Financial Officer, Chief Operating Officer · since 2015
Alexander Scheer
Chief Scientific Officer · since 2016
Alex Dusek
Vice President - Commercial Strategy
Jean-Sebastien Cleiftie
Director of Business Development and Licensing · since 2017
Iman El-Hariry
Chief Medical Officer
Gil Beyen
Chief Executive Officer, Director · since 2019
Jean-Paul Kress
Chairman of the Board · since 2019
URL
https://erytech.com/
IPO date
May 07, 2013
Employees
49
Domiciled in
FR
Incorporated in
FR
Headquarters & legal address
60 AVENUE ROCKEFELLER
LYON 69008
FR
Trading name
ERYTECH PHARMA
Previous name
ERYTECH PHARMA

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT